Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
May 17 2018 - 8:00AM
Chief Medical Officer Dr. Frederic Triebel
to Present at the 3rd Annual Advances in Immuno-Oncology
Congress
Immutep Limited (ASX:IMM) (NASDAQ:IMMP) ("Immutep“ or “the
Company“), a biotechnology company developing novel immunotherapy
treatments for cancer and autoimmune diseases, advises that its
Chief Medical Officer and Chief Scientific Officer, Dr. Frédéric
Triebel, will present interim results from the three initial
patient cohorts of its ongoing TACTI-mel Phase I clinical trial in
a global webcast and Q&A. The webcast will also include an
update on the Company’s clinical immuno-oncology combination
program.
Dr. Triebel will also present a subset of these interim results
at the 3rd Annual Advances in Immuno-Oncology Congress, on 25 May
2018 in London, UK. The presentation, titled “Two ACTIve
Immunotherapies in melanoma (TACTI-mel): results of a phase I trial
with metastatic melanoma patients treated with a soluble LAG-3
receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting
(APC) activator combined with pembrolizumab” will be released to
the market to coincide with the event and made available on the
Company’s website.
Immutep’s current lead product is eftilagimod alpha (“efti” or
“IMP321”), a potential first-in-class major histocompatibility
complex class II (“MHC II”) agonist and antigen presenting cell
(“APC”) activator. Efti is a soluble LAG-3Ig fusion protein based
on the LAG-3 immune control mechanism. This mechanism plays a vital
role in the regulation of the T cell immune response. Efti, unlike
blocking antibodies, is unique as it uses LAG-3 itself as a tool to
activate the immune system via MHC II molecules.
The TACTI-mel Phase I clinical trial is a multi-center,
open-label clinical trial evaluating the combination of efti with
pembrolizumab (KEYTRUDA®) for unresectable or metastatic
melanoma. As previously disclosed, interim results from the
first three cohorts was expected in H1 2018. The trial remains
ongoing, following its expansion by an additional cohort, with
results from this additional cohort expected in H2 2018.
Investor Webcast Details
The webcast will be hosted by Dr. Triebel, Marc Voigt, CEO and
Christian Mueller, Director of Clinical Development.
Date & Time: Wednesday, May 30, 2018,
8:00am Australian Eastern Standard Time
Tuesday, May 29,
2018, 6:00pm US Eastern Daylight Time
Register: Interested investors can register via
a link to the webcast on the Company’s website at Clinical Results
of Ongoing Melanoma Study and Update on Eftilagimod Alpha Clinical
Development Strategy or via the following
link.https://fnn.webex.com/fnn/onstage/g.php?MTID=edd0388586f757aa2ea7d890e6193f64a
A replay of the webcast will also be available at
www.immutep.com from the day after the event.
About the TACTI-mel clinical trial
The ongoing TACTI-mel (Two ACTive Immunotherapies in melanoma)
Phase I clinical trial is a multi-center, open-label, dosing
escalating (1, 6 or 30 mg of eftilagimod alpha or “efti”) study
evaluating the combination of efti with pembrolizumab for 6 months,
starting at treatment cycle 5 in unresectable or metastatic
melanoma patients that have had either a suboptimal response or had
disease progression with pembrolizumab monotherapy
(clinicaltrials.gov identifier NCT 02676869). The initial study
consists of three cohorts of six patients.
In February 2018, Immutep expanded the TACTI-mel study by an
additional cohort of 6 patients at 30 mg of efti in combination
with pembrolizumab starting at cycle 1 and with a treatment
duration of 12 months. As announced on March 22, 2018, the
first patient from this additional cohort has received their first
dose.
About Immutep
Immutep is a globally active biotechnology company that is a
leader in the development of immunotherapeutic products for the
treatment of cancer and autoimmune disease. Immutep is dedicated to
leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximize value to
shareholders. Immutep is listed on the Australian Securities
Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep’s current lead product is eftilagimod alpha (“efti” or
“IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3
immune control mechanism. This mechanism plays a vital role in the
regulation of the T cell immune response. Efti is currently in a
Phase IIb clinical trial as a chemoimmunotherapy for metastatic
breast cancer termed AIPAC (clinicaltrials.gov identifier NCT
02614833) and a Phase I combination therapy trial in metastatic
melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT
02676869). Additional LAG-three products, including antibodies, for
immune response modulation in autoimmunity and cancer are being
developed by Immutep’s large pharmaceutical partners. Immutep is
also developing an agonist of LAG-3 (IMP761) for autoimmune
disease.
For the latest company presentation slides, please visit
http://www.immutep.com/investors-media/presentations.html
For the latest video update on Immutep, please visit the Video
section of the Company’s website.
Further information can be found on the
Company’s website www.immutep.com or by contacting:
U.S. Investors:Jay Campbell,
Vice President of Business Development and Investor Relations,
Immutep Limited+1 (917) 860-9404; jay.campbell@immutep.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
U.S. Media:Sharon Golubchik,
Antenna Group+1 (201) 465-8008; sharon@antennagroup.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jul 2023 to Jul 2024